Related Experiment Video For Clostridioides difficile
Updated: May 10, 2025
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Molecular typing and clinical characteristics of Clostridioides difficile infection in patients with inflammatory
Jiayiren Li1, Jing Yang1, Zirou Ouyang1
1Hebei Provincial Center for Clinical Laboratories, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Objectives:
The increasing incidence of Clostridioides difficile infection (CDI) has been associated with poorer prognosis of patients with inflammatory bowel disease (IBD). However, relevant data are limited in China. The aim of this study was to clarify the molecular types and clinical characteristics of C. difficile in IBD patients in China.
Methods:
Stool samples were collected, cultured anaerobically, and tested for glutamate dehydrogenase and C. difficile toxins A and B. Toxigenic C. difficile isolates were subjected to multi-locus sequence typing and antimicrobial susceptibility testing. Clinical data were collected to compare IBD and non-IBD patients with CDI, and to determine the risk factors associated with CDI in IBD patients.
Results:
The incidence of CDI was significantly higher in IBD patients than non-IBD patients (27.2% vs. 9.0%, respectively). Among IBD patients, the dominant sequence types (STs) were ST54 (20.2%), ST2 (14.9%), ST3 (14.9%), and ST42 (13.2%). The STs with the highest multidrug resistance rates were ST37 (100%), ST35 (100%), and ST42 (73.3%). In IBD patients, hospitalization within 6 months and use of 5-aminosalicylic acid were independent risk factors for CDI. Other risk factors included the use of proton pump inhibitors, immunosuppressants, and corticosteroids.
Conclusion:
The incidence of CDI was significantly higher in IBD patients than non-IBD patients. Surveillance of CDI in hospitalized patients should be strengthened to reduce the incidence of CDI in IBD patients.
More Related Videos
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF